Abstract-␤ 2 -Adrenoceptors are important modulators of vascular tone, particularly in the pulmonary circulation. Because neurohormonal activation occurs in pulmonary arterial hypertension, we have investigated the effect of different adrenergic vasoactive substances on tone regulation in large and small pulmonary arteries, as well as in systemic vessels of mice. We found that the ␤ 2 -adrenoceptor antagonist ICI 118,551 (ICI) evoked a decrease of vascular tone in large pulmonary arteries and reduced the sensitivity of pulmonary arteries toward different contracting agents, eg, norepinephrine, serotonin, or endothelin. ICI proved to act specifically on pulmonary vessels, because it shifted the dose-response curve of norepinephrine to the right in pulmonary arteries, whereas there was no effect in the aorta. Pharmacological experiments proved that the right shift of the norepinephrine dose-response curve by ICI was mediated via a ␤ 2 -adrenoceptor/G i/o protein-dependent pathway enhancing NO production in the endothelium; these results were corroborated in ␤-adrenoceptor and endothelial NO synthase knockout mice where ICI had no effect. ICI increased vascular lumen diameter in lung sections and reduced pulmonary arterial pressure under normoxia and under hypoxia in the isolated perfused lung model. These effects were found to be physiologically relevant, because ICI specifically decreased pulmonary but not systemic blood pressure in vivo. Thus, the ␤ 2 -adrenoceptor antagonist ICI is a pulmonary arterial-specific vasorelaxant and, therefore, a potentially interesting novel therapeutic agent for the treatment of pulmonary arterial hypertension. (Hypertension. 2009;54:00-00.)
␤
-Adrenoceptors (␤-ARs) can couple to G s , G i/o and/or G q proteins and have an important vasorelaxing function in the systemic and pulmonary circuits. All of the isoforms that are known so far (␤ 1 -, ␤ 2 -, ␤ 3 , and low-affinity-state ␤ 1 -AR) have been identified in pulmonary vessels, [1] [2] [3] with the ␤ 2 -AR being the most potent for vasorelaxation. 4 The pulmonary arteries (PAs) are important therapeutic targets, because pulmonary arterial hypertension often occurs after cardiac surgery in children 5 but also in adults and can result in life-threatening right heart failure. Therefore, specific and fast-acting vasodilators for PAs are urgently needed. However, most drug treatment regimens also strongly decrease vascular tone in the systemic circuit, leading to hypotension.
Other than ␤-AR agonists, ␤-blockers were also reported to show promising results in the treatment of pulmonary arterial hypertension, which was not caused by left ventricular disorders. 6 In systemic arteries, it has been demonstrated that thirdgeneration ␤-blockers can directly induce vasodilation via NO release from the endothelium 7 and thereby positively affect the afterload. The aim of our study was to identify pulmonary specific vasorelaxants, and we have, therefore, investigated the impact of different ␤-adrenergic mediators on vascular tone in the pulmonary and systemic circulations of mouse. We have identified ICI 118,551 (ICI), a ␤-blocker with antagonist activity at ␤ 2 -AR that is known to be Ͼ500-fold selective over ␤ 1 -and ␤ 3 -AR, 8 as an interesting candidate. Pharmacological studies revealed ␤ 2 -AR blockade in isolated tissues, in animals, and in humans by ICI. 9, 10 Moreover, inverse agonist properties of ICI were demonstrated in a transgenic mouse model of ␤ 2 -AR overexpression, where the increased baseline tension in the left atrium could be diminished by ICI binding, shifting the equilibrium of the ␤ 2 -AR to the inactive state. 11 In the present study, we have found that the specific ␤ 2 -AR blocker ICI acts as an agonist that induces vasorelaxation via a G i/o protein/NO-coupled pathway specifically in PA and may, therefore, be used for the therapy of pulmonary arterial hypertension.
Methods
Please see the online data supplement available at http://hyper. ahajournals.org.
Results

ICI Reduces the Sensitivity of PAs to Different Vasoconstrictors
To identify vasoactive substances that are specific for pulmonary vessels, we have investigated the effect of adrenergic agonists and antagonists on vascular tone of murine PAs and aortas (AOs). These vessels were chosen because they are of similar size and easily accessible.
We found that the ␤ 2 -AR-specific inverse agonist ICI (10 mol/L) induced a prominent vasorelaxation of norepinephrine (NE)-precontracted PA but not AO ( Figure 1A) Figure S1A through S1C, available in the online data supplement.
Vascular reactivity to NE is particularly important, because pulmonary arterial hypertension has been reported to often be associated with elevated blood levels of NE, which are also significant predictors of mortality. 5 Figure 1B ).
To test the potential of other ␤-blockers to influence NE vasoreactivity, we preincubated PAs and AOs with the ␤ 1 -AR antagonist metoprolol. This treatment was without effect on NE dose response. Similarly, the specific ␤ 3 -antagonist SR 59230A (SR; 10 mol/L) only evoked a minor shift of NE dose response in PAs and AOs. Because the reduction of sensitivity to vasoconstrictors could be an effect of ␤ 2 -AR antagonists in general, we also examined the effect of other ␤ 2 -AR blockers. However, the ␤ 1 /␤ 2 -blocker propranolol and the ␤ 2 -AR specific antagonist butoxamine (Butox) only slightly decreased the sensitivity toward NE in PAs (Table  S1 ). This suggests that the reduction of vasoreactivity toward NE by ICI is not a general effect of all ␤ 2 -AR antagonists but a specific property of this compound.
ICI Selectively Reduces NE Sensitivity via ␤ 2 -Adrenoceptors
To rule out possible unspecific effects of ICI that could be independent from ␤-ARs, we tested the impact of ICI on NE dose response in ␤-AR knockout mice where ␤ 1 -, ␤ 2 -, and ␤ 3 -ARs are absent. 13 In these mice, the right shift of NE dose response in PAs by ICI was found to be abrogated (pEC 50 Figure 2A ). Thus, ICI reduced the sensitivity toward NE in PAs via ␤-ARs. To further investigate the specific receptor subtype involved, the vessels of wild-type mice were preincubated with the ␤ 3 -ARselective antagonist SR or the specific ␤ 1 -AR blocker CGP 20712A (300 nmol/L). In both cases, the treatment did not affect the right shift of the NE dose-response curve by ICI (pEC 50 Figure 2C ), indicating that neither ␤ 1 -nor ␤ 3 -AR was involved. The mediation of the effect of ICI by ␤ 2 -AR was also corroborated by the pretreatment of vascular rings with Butox (10 mol/L), which led to a strong attenuation of the right shift, especially at low NE concentrations (pEC 50 Figure 2D ). Thus, ICI decreased the sensitivity toward NE in PA by ␤ 2 -AR. However, the pulmonary arterial specificity of the compound is not related to the number of ␤ 2 -ARs in PAs or AOs, because immunostainings revealed a similar distribution in both vessels ( Figure 2E ), and semiquantitative analysis of Western blot experiments confirmed equal amount of ␤ 2 -ARs in bovine pulmonary endothelial cells (bPAECs) and bovine aortic endothelial cells (bAECs) ( Figure 2F ). Figure 3A ). Thus, ICI reduced the sensitivity of PA to NE by activation of G i/o proteins. Vasorelaxation is often mediated via endothelium-derived factors like NO. Therefore, we assessed the contribution of the pulmonary vascular endothelium in ICI signaling. Removal of the endothelium alone had no effect on the cumulative NE concentration response (pEC 50 Figure 3B ), indicating that ICI evoked the release of endotheliumdependent mediators, which lowered NE sensitivity. The complete removal of the endothelium in our preparation was confirmed by immunostaining with CD31 ( Figure 3C ). The impact of NO was determined after incubation with the endothelial NO synthase (eNOS) inhibitor N G -nitro-Larginine methyl ester (L-NAME; 100 mol/L). This substance strongly inhibited the right shift of the dose-response curve by ICI (pEC 50 : 7.89Ϯ0.17, nϭ4 [NEϩL-NAMEϩICI], PϾ0.05 versus 8.02Ϯ0.23, nϭ4 [NEϩL-NAME; Figure 3D ). L-NAME alone had no effect on NE dose response in PAs but increased sensitivity to NE at low concentrations in AOs (data not shown). The important role of the eNOS was further proven using vessels from eNOS KO mice where ICI had no effect on NE dose response (pEC 50 Figure 3E ). The critical contribution of NO production to the vascular response to ICI was corroborated by fluorescence measurements with the NO indicator diaminofluorescein-IM diacetate (DAF-FM DA), revealing that ICI induced NO production (relative NO increase: 46.9Ϯ7.8%) in bPAECs, which was significantly higher compared with the steady-state NO release under control conditions (relative NO increase: 19.5Ϯ3.7%, PϽ0.05 versus ICI; Figure 3F ). The activation of the eNOS by ICI could be attributed to a time-dependent phosphorylation of the eNOS at Ser1177, which was demonstrated in Western blotting experiments after incubation of bPAECs for 2, 5, and 10 minutes ( Figure  3G and 3H) . From these data we conclude that ICI reduces 
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ICI Decreases the Tone of Small Intra-PAs
To directly assess pulmonary vascular diameter, we applied the lung section technique established by Perez and Sanderson. 15 We found that the ␤ 2 -adrenergic inverse agonist ICI (10 mol/L) increased the lumen area of PA from 33.33Ϯ7.17% to 78.29Ϯ12.74% (nϭ4; PϽ0.05), after precontraction with 5-HT ( Figure 4A through 4C) , hence a prominent vasorelaxing effect (Ϸ70%; Figure 4C ). To examine whether ICI also affected the small precapillary arteries, we have used the isolated perfused lung (IPL) system. Here, ICI reduced pulmonary arterial pressure after 5-HT precontraction from 4.51Ϯ1.32 mm Hg (6.15Ϯ1.80 cm H 2 O) to 1.94Ϯ0.74 mm Hg (3.51Ϯ1.12 cm H 2 O; nϭ7; PϽ0.05); this is equivalent to a pressure decrease of Ϸ60% ( Figure 5A and 5B). The effect of ICI in the IPL was dose-dependent in the range of 0.01 to 10.00 mol/L ( Figure 5C and 5D) . In contrast to our findings in the IPL in large PAs, only concentrations of ICI Ͼ1 mol/L (Յ10 mol/L) evoked a dose-dependent relaxation ( Figure S1D ), demonstrating that these vessels are less sensitive to ICI than the small intra-PAs; responses were independent of the precontracting agent, because vasorelaxation induced by ICI (10 mol/L) was similar after 5-HT (31.0Ϯ7.4%) or NE (33.4Ϯ10.0%) precontraction.
One of the main pathophysiological causes of pulmonary arterial hypertension is hypoxia. We, therefore, tested the potential of ICI to reduce the vascular pressure after hypoxic vasoconstriction. Our experiments revealed that ICI attenuated the hypoxia (0% O 2 )-induced pressure increase of pulmonary vessels by 33% (Figure 5E and 5F). Thus, ICI decreases pulmonary vascular pressure by its vasodilatory action on small PAs under normoxic and hypoxic conditions.
ICI Reduces Pulmonary but not Systemic Pressure In Vivo
To prove the specificity and the physiological relevance of the ICI-induced vasorelaxation, we performed in vivo catheter measurements. Blood pressure was measured in the sedated mouse after injecting ICI (0.2 mg/kg; 6 L over 40 seconds) into the jugular vein. Systolic pressure values directly after the injection were compared with those obtained 2 minutes later. The analysis showed that ICI reduced systolic pressure in the pulmonary circuit from 32.3Ϯ3.1 mm Hg to 23.9Ϯ2.6 mm Hg (nϭ5; Pϭ0.03), which corresponds with a pressure decrease of 25% ( Figure 6A ). In contrast, systolic systemic pressure values remained stable at 113.0Ϯ8.1 mm Hg directly after injection and at 112.8Ϯ13.8 mm Hg (nϭ5; PϾ0.05) 2 minutes later ( Figure 6B) . Thus, ICI strongly reduces pulmonary but not systemic arterial pressure in vivo.
Discussion
In the current study we show that even low concentrations of the specific ␤ 2 -AR inverse agonist ICI selectively reduced the sensitivity of PAs but not of systemic vessels to different vasoconstrictors. This finding is physiologically relevant, because it occurred in large and in small intra-PAs under normal and hypoxic conditions. The response was a specific property of ICI, because it was not mimicked by other ␤-blockers, regardless of whether these were either ␤ 2 specific or not. Although in most of the experiments we used high concentrations of ICI to obtain strong effects, in the IPL there was a dose-dependent vasorelaxation already starting at a very low concentration of 0.01 mol/L, which was in good agreement with the reported EC 50 of 0.06 mol/L for ICI binding to ␤ 2 -AR. 16 A direct effect on ␣-AR-mediated precontraction can be excluded, because ICI also affected dose-response curves of vasoconstrictors, which are devoid of adrenergic activity, eg, endothelin and 5-HT; moreover, ICI was without effect in ␤-AR KO mice with intact ␣-AR signaling. In addition, the observed differences of the response to ICI in pulmonary versus systemic vessels were not caused by the different expression or distribution of ␤ 2 -AR, because Western blots in bPAECs and bovine aortic endothelial cells, as well as immunostainings in PAs and AOs, yielded similar results. We, therefore, suggest that differences in G protein coupling most likely account for the differential effect of ICI. There is accumulating evidence that G proteincoupled receptors can couple to more than one G protein, and different agonist-induced conformations exist with different efficacies for coupling to particular G proteins. This type of ligand behavior has been termed "functional selectivity" or "stimulus trafficking" 17 and may also depend on the cell type. Hence, ICI-induced ␤ 2 -AR coupling to G i/o proteins could differ in pulmonary and systemic endothelial cells. Other than quantitative differences in G protein activation, differential coupling to specific G␣ i/o subtypes may also occur. This important concept could be addressed in future studies by means of guanosine 5Ј-[␥-thio]triphosphate assays or photolabeling and immunoprecipitation of G i/o proteins. Furthermore, the downstream signaling of ICI-induced G i/o protein activation could also differ in endothelial cells from the pulmonary and the systemic circuits.
Although other studies reported ICI as an antagonist of isoprenaline-induced vasorelaxation in rat PAs, 4 we demonstrate a vascular tone decrease evoked by this specific compound in mice. These contrasting results could be explained by different basal receptor activities, which play an important role for inverse agonists like ICI. Vasorelaxation by PTX-sensitive G proteins is often transmitted via endo- thelial NO production. 14 We provide convincing evidence for the involvement of NO in the ICI-mediated vasorelaxation of pulmonary vessels, because the right shift of NE doseresponse curves was blocked by the removal of the endothelium, by treatment with the eNOS inhibitor L-NAME, and by using vessels from eNOS KO mice. Moreover, NO measurements with the fluorescence dye DAF-FM DA in bPAECs support these findings.
In recent years, NO production in response to ␤-blockers has already been described. Many ␤-blockers were reported to possess intrinsic activity of their own. 18, 19 For example, the third-generation ␤ 1 -blocker nebivolol was shown to have agonistic effects at endothelial ␤ 3 -AR, thereby leading to enhanced NO production and vasorelaxation. 9 However, our data clearly show that ␤ 3 -AR is not involved in the reduction of NE sensitivity by ICI. Although our in vivo experiments support the idea that the effect of ICI is mediated via NO, we cannot exclude that eicosanoids, mast cell degranulation, and/or histamine-dependent mechanisms also contribute to the observed vasodilation, 20, 21 because these pathways are also influenced by ␤-adrenergic signaling. 22 One of the main concerns of most pharmacological vasorelaxants in the treatment of pulmonary hypertension is their pronounced hypotensive effect on systemic vessels. However, in the case of ICI, we found that it selectively reduced pulmonary but not systemic vascular tone in vivo. In accordance with our data, 2 different studies in humans also reported that ICI did not affect systemic blood pressure. 23, 24 Only Vincent et al 25 found a reduction of systemic blood pressure, however, only 1 week after the beginning of treatment and when using a much higher concentration (0.7 mg/kg for patients of 70-kg weight) compared with our study. Thus, low concentrations of ICI specifically reduce vascular tone in pulmonary vessels. The acute reduction of pulmonary arterial pressure by ICI could be clinically beneficial in states of acute pulmonary arterial hypertension crises. Moreover, it may prevent persisting high pressure in the pulmonary circulation, which has been reported to be an important factor in the pathophysiology of chronic pulmonary arterial hypertension. 26 Whether ICI can also attenuate vascular remodeling remains to be investigated in future studies.
Perspectives
Altogether, we show that the ␤-blocker ICI has agonist activity at the ␤ 2 -AR, whereby it decreases vascular tone of PAs selectively via a G i/o protein-dependent NO increase. This finding shows that distinct substances independent from their class properties may have special features that can be exploited for therapeutic use.
